NCT05405725 - A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® | Biotech Hunter

Enrollment

504

Participants

Timeline

Start Date

July 4, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

August 31, 2024

Conditions

Postmenopausal Osteoporosis

Interventions

BIOLOGICAL

ENZ215

Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)

BIOLOGICAL

Prolia

Enrolled women with postmenopausal osteoporosis will receive Prolia

Trial Locations (1)

RECRUITING

MEDICAL PLUS s.r.o., Uherské Hradiště